Direxion Daily S&P Biotech Bull 3X ETF

ProShares UltraPro Short S&P500

iPath S&P 500 VIX ST Futures ETN

Direxion Daily 20+ Yr Trsy Bull 3X ETF

ProShares Ultra Silver

SPDR S&P Biotech ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Financial Bull 3X ETF

ProShares Trust ProShares Short Bitcoin Strategy ETF

Direxion Daily S&P Biotech Bear 3X ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

Direxion Daily 20+ Yr Trsy Bear 3X ETF

ProShares UltraShort Silver

ProShares Short VIX Short-Term Futures

ProShares Ultra Bloomberg Natural Gas

Direxion Financial Bear 3X Shar

The Communication Services Select Sector SPDR Fund

iShares MSCI Brazil Capped

Bank Of Montreal

C3.ai Inc. Class A Common Stock

UiPath Inc. Class A Common Stock

JELD-WEN Holding Inc. Common Stock

Dell Technologies Inc. Class C Common Stock

Granite Point Mortgage Trust Inc. Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Estee Lauder Companies Inc. (The) Common Stock

Hexcel Corporation Common Stock

Reddit Inc. Class A Common Stock

Alexandria Real Estate Equities Inc. Common Stock

SentinelOne Inc. Class A Common Stock

NuScale Power Corporation Class A Common Stock

Arista Networks Inc. Common Stock

QuantumScape Corporation Class A Common Stock

Bath & Body Works Inc.

Under Armour Inc. Class A Common Stock

Trio Petroleum Corp. Common Stock

Victorias Secret & Co. Common Stock

GameStop Corporation Common Stock

Uber Technologies Inc. Common Stock

Click here to get full coverage on Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha

Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW)  Seeking Alpha

Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings  Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

Click here to get full coverage on Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy  Stock Titan

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Click here to get full coverage on Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results  Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Click here to get full coverage on HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More  Nasdaq

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Harrow Inc (HROW) Stock Price Down 3.78% on May 22 - GuruFocus

Harrow Inc (HROW) Stock Price Down 3.78% on May 22  GuruFocus

Harrow Inc (HROW) Stock Price Down 3.78% on May 22 - GuruFocus

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Click here to get full coverage on Harrow to Present at Two Investor Conferences in May - Business Wire

Harrow to Present at Two Investor Conferences in May  Business Wire

Harrow to Present at Two Investor Conferences in May - Business Wire

Click here to get full coverage on Harrow Announces First-Quarter 2025 Financial Results - Stock Titan

Harrow Announces First-Quarter 2025 Financial Results  Stock Titan

Harrow Announces First-Quarter 2025 Financial Results - Stock Titan

Click here to get full coverage on Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Nasdaq

Harrow (HROW) Q4 Earnings and Revenues Top Estimates  Nasdaq

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Nasdaq

Click here to get full coverage on Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Harrow: A Name I Am Accumulating (NASDAQ:HROW)  Seeking Alpha

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee  Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Click here to get full coverage on Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)  Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...  Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Click here to get full coverage on Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership  Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Click here to get full coverage on TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News  Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus

Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth  GuruFocus

Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus

Click here to get full coverage on Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27  Stock Titan

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Click here to get full coverage on Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”  Insider Monkey

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey

Click here to get full coverage on Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW  Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Click here to get full coverage on Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price - simplywall.st

Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price  simplywall.st

Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price - simplywall.st

Click here to get full coverage on Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW)  Seeking Alpha

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients  Business Wire

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Click here to get full coverage on Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025  Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Click here to get full coverage on Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory  Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus

Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO  GuruFocus

Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus

Click here to get full coverage on Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®  Business Wire

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Click here to get full coverage on Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi  GuruFocus

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus

Click here to get full coverage on NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)  PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

Click here to get full coverage on Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga

Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock  Benzinga

Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga

Click here to get full coverage on Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM  Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Click here to get full coverage on Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook  RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Click here to get full coverage on Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol  Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Click here to get full coverage on Harrow: Q1 Earnings Snapshot - MySA

Harrow: Q1 Earnings Snapshot - MySA

Click here to get full coverage on Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com

Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share  marketscreener.com

Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com

Click here to get full coverage on Borrowing Cash To Burn It: The Curious Case Of Harrow (NASDAQ:HROW) - Seeking Alpha

Borrowing Cash To Burn It: The Curious Case Of Harrow (NASDAQ:HROW)  Seeking Alpha

Borrowing Cash To Burn It: The Curious Case Of Harrow (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 | HROW Stock News - GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 | HROW Stock News  GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 | HROW Stock News - GuruFocus

Click here to get full coverage on Harrow Announces Nashville Expansion - Business Wire

Harrow Announces Nashville Expansion  Business Wire

Harrow Announces Nashville Expansion - Business Wire

Click here to get full coverage on What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings  GuruFocus

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Click here to get full coverage on Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 - Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025  Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 - Business Wire

Click here to get full coverage on Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients  Business Wire

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire

Click here to get full coverage on Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Harrow Announces Second Quarter 2024 Financial Results  Business Wire

Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch  GuruFocus

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus

Click here to get full coverage on Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL  Business Wire

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Click here to get full coverage on Harrow Announces Market Access Wins for VEVYE® - Business Wire

Harrow Announces Market Access Wins for VEVYE®  Business Wire

Harrow Announces Market Access Wins for VEVYE® - Business Wire

Click here to get full coverage on Where Harrow Stands With Analysts - Benzinga

Where Harrow Stands With Analysts  Benzinga

Where Harrow Stands With Analysts - Benzinga

Click here to get full coverage on Harrow Health (HROW) Surpasses Q4 Earnings and Revenue Expectati - GuruFocus

Harrow Health (HROW) Surpasses Q4 Earnings and Revenue Expectati  GuruFocus

Harrow Health (HROW) Surpasses Q4 Earnings and Revenue Expectati - GuruFocus

Click here to get full coverage on Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.  Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Click here to get full coverage on Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts - Investing.com

Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts  Investing.com

Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts - Investing.com

Click here to get full coverage on Harrow Health Delays 10-K Filing for 2024 - TipRanks

Harrow Health Delays 10-K Filing for 2024  TipRanks

Harrow Health Delays 10-K Filing for 2024 - TipRanks

Click here to get full coverage on Harrow Provides TRIESENCE® Relaunch Update - Business Wire

Harrow Provides TRIESENCE® Relaunch Update  Business Wire

Harrow Provides TRIESENCE® Relaunch Update - Business Wire

Click here to get full coverage on Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW) - Seeking Alpha

Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW)  Seeking Alpha

Harrow Successfully Manufactures Triesence; Management Credibility Soars (HROW) - Seeking Alpha

Click here to get full coverage on Harrow: Q1 Earnings Snapshot - San Francisco Chronicle

Harrow: Q1 Earnings Snapshot  San Francisco Chronicle

Harrow Health Inc (HROW)

Price Chart

Key Statistics

Technicals

About HROW

Latest News

Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Advanced Charts

Top Gainers

Top Losers